First Case Report of Adalimumab-Induced Psoriasis in Crohn's Disease

Ustekinumab is a biologic agent with Food and Drug Administration approval for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease. It functions to inhibit the p40 subunit common to both interleukin-12 and interleukin-23. These pro-inflammatory cytokines are implicated in autoinflammatory and autoimmune disorders, but they also play an important role in cell-mediated immunity against viral, bacterial, and fungal pathogens. Therefore, antagonism of interleukin-12 and interleukin-23 by ustekinumab may increase the risk of human papillomavirus infection or reactivation which can lead to the development of verrucae. To the best of our knowledge, there is only one published report of disseminated verrucosis secondary to ustekinumab treatment for psoriasis. Here, we present the first case report of ustekinumab-induced disseminated verrucosis occurring in the setting of treatment for Crohn’s disease.

Download Full-text

Squamous cell carcinoma in enterocutaneous fistula associated with Crohn's disease: First case report: Figure 1

Journal of Crohn s and Colitis ◽

10.1016/j.crohns.2014.02.017 ◽

2014 ◽

Vol 8 (9) ◽

pp. 1142-1143 ◽

Cited By ~ 4

Author(s):

Teresa Pinto Pais ◽

Sónia Fernandes ◽

João Carvalho

Keyword(s):

Squamous Cell Carcinoma ◽

Crohn’S Disease ◽

Case Report ◽

Crohn's Disease ◽

Cell Carcinoma ◽

Squamous Cell ◽

Enterocutaneous Fistula ◽

First Case

Download Full-text

Mediterranean spotted fever in a patient with Crohn's disease under adalimumab: First case report and review of the literature

Gastroenterología y Hepatología ◽

10.1016/j.gastrohep.2014.05.013 ◽

2015 ◽

Vol 38 (6) ◽

pp. 379-380 ◽

Cited By ~ 1

Author(s):

João Santos-Antunes ◽

Amadeu C.R. Nunes ◽

Guilherme Macedo

Keyword(s):

Crohn’S Disease ◽

Case Report ◽

Crohn's Disease ◽

Spotted Fever ◽

Mediterranean Spotted Fever ◽

Review Of The Literature ◽

First Case

Download Full-text

Bacteremia Due to Clostridium Difficile: Case Report and Review of the Literature

Clinical Medicine Case Reports ◽

10.4137/ccrep.s2204 ◽

2009 ◽

Vol 2 ◽

pp. CCRep.S2204 ◽

Cited By ~ 1

Author(s):

Cherag Daruwala ◽

Giancarlo Mercogliano ◽

Gary Newman ◽

Mark J. Ingerman

Keyword(s):

Crohn’S Disease ◽

Case Report ◽

Mortality Rate ◽

Crohn's Disease ◽

Disease Patient ◽

Review Of The Literature ◽

First Case ◽

Polymicrobial Bacteremia ◽

Overall Mortality ◽

Significant Mortality

Objective The purpose of this study is to report a case of C. difficile bacteremia in a Crohn's disease patient and to review the literature on previously reported cases. Methods Searches of MEDLINE and PubMed databases were made. Results We report the first case of C. difficile bacteremia in a Crohn's disease patient. There are 15 other reported cases of C. difficile bacteremia reported in the literature. We found that the majority of patients (10 of 15 patients) had polymicrobial bacteremia and that the overall mortality rate is significant, with 6 of 15 reported patients dying. Conclusion In conclusion, we find that C. difficile bacteremia is associated with a significant mortality rate and it would seem prudent to consider aggressive antibiotic therapy.

Download Full-text